The NCCN 2021 Annual Conference convened virtually March 18-20, drawing attendees from more than 40 countries to discuss updates to NCCN's Oncology Clinical Practice Guidelines, new and emerging therapies, best practices in oncology care, as well as keynote sessions on HPV vaccinations, racial disparities in guideline-adherent cancer care, and effects of the pandemic on cancer care.
About Sam BarnumThis author has not yet filled in any details.
So far Sam Barnum has created 32 blog entries.
A leading global device manufacturer faced a pricing strategy challenge and partnered with BHA to identify appropriate prices for a suite of three products aimed at the low-end, mid-range, and high-end of the urology market.
Currently, there are approximately 2800+ county-level administrative regions in China, and over 70% of the total Chinese population resides in these counties, more commonly referred to as “the rural areas of China”.
As the new year begins, we are looking ahead to four key megatrends that we expect to shape the landscape in the year to come.
As a result of Brexit, the In Vitro Diagnostic Medical Device Regulations (IVDR) will not apply to Great Britain. Unlike Great Britain, the IVDR will apply in Northern Ireland from 26 May 2022.
BHA Partners with Alcon to Conduct Real-World Study Highlighting Efficiencies of Optical Biometer in Cataract SurgerySam Barnum2020-12-15T16:09:39-05:00
Alcon, a global leader in eye care, collaborated with Boston Healthcare to conduct a Time-and-Motion Study to support the value communication of its novel swept-source optical coherence tomography biometer, ARGOS®.
In November 2020, two years following the implementation of the national centralized tender program that started with biopharmaceuticals, the first medical device was targeted - drug-eluting coronary stents.
The pilot of implementing a diagnosis-related group (DRG) payment model to inpatient hospital care, a major initiative of China’s ongoing healthcare reform, started in 2019. Boston Healthcare Associates has been vigilant in tracking this strategic topic given the implications on the industry and the healthcare ecosystem as a whole.
Eight leaders in Life Sciences came together for a virtual breakfast roundtable devoted to leading Life Sciences organizations through these unprecedented times.
CMS Proposes Changes to Part B Medicare Reimbursement for Physician-Administered Drugs Approved Under the 505(b)(2) Approval PathwaySam Barnum2020-11-02T11:46:40-05:00
The Centers for Medicare and Medicaid Services (CMS) intends to alter assignment of Healthcare Common Procedure Coding System (HCPCS) Level II codes for certain physician-administered 505(b)(2) drugs.